Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropharmacology ; 225: 109354, 2023 03 01.
Article in English | MEDLINE | ID: mdl-36460082

ABSTRACT

Pain sensitization is a phenomenon that occurs to protect tissues from damage and recent studies have shown how a variety of non-noxious stimuli included in our everyday lives can lead to pain sensitization. Consumption of large amounts of alcohol over a long period of time invokes alcohol use disorder (AUD), a complex pathological state that has many manifestations, including alcohol peripheral neuropathy (neuropathic pain). We asked if 'non-pathological' alcohol consumption can cause pain sensitization in the absence of other pathology? Studies have pointed to glia and other immune cells and their role in pain sensitization that results in cell and sex-specific responses. Using a low-dose and short-term ethanol exposure model, we investigated whether this exposure would sensitize mice to a subthreshold dose of an inflammatory mediator that normally does not induce pain. We observed female mice exhibited specific mechanical and higher thermal sensitivity than males. We also observed an increase in CD68+ macrophages in the ipsilateral dorsal root ganglia (DRG) and Iba1+ microglia in the ipsilateral spinal dorsal horn of animals that were exposed to ethanol and injected with subthreshold inflammatory prostaglandin E2. Our findings suggest that short-term ethanol exposure stimulates peripheral and central, immune and glial activation, respectively to induce pain sensitization. This work begins to reveal a possible mechanism behind the development of alcoholic peripheral neuropathy.


Subject(s)
Ethanol , Hyperalgesia , Neuralgia , Sex Characteristics , Animals , Female , Male , Mice , Ethanol/adverse effects , Ganglia, Spinal/pathology , Hyperalgesia/chemically induced , Macrophages/drug effects , Macrophages/pathology , Microglia/drug effects , Microglia/pathology , Neuralgia/chemically induced , Neuralgia/pathology , Neuroglia/drug effects , Neuroglia/pathology , Alcoholism/complications
2.
Front Immunol ; 12: 642420, 2021.
Article in English | MEDLINE | ID: mdl-33912169

ABSTRACT

Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect that occurs in up to 63% of patients and has no known effective treatment. A majority of studies do not effectively assess sex differences in the onset and persistence of CIPN. Here we investigated the onset of CIPN, a point of therapeutic intervention where we may limit, or even prevent the development of CIPN. We hypothesized that cap-dependent translation mechanisms are important in early CIPN development and the bi-directional crosstalk between immune cells and nociceptors plays a complementary role to CIPN establishment and sex differences observed. In this study, we used wild type and eIF4E-mutant mice of both sexes to investigate the role of cap-dependent translation and the contribution of immune cells and nociceptors in the periphery and glia in the spinal cord during paclitaxel-induced peripheral neuropathy. We found that systemically administered paclitaxel induces pain-like behaviors in both sexes, increases helper T-lymphocytes, downregulates cytotoxic T-lymphocytes, and increases mitochondrial dysfunction in dorsal root ganglia neurons; all of which is eIF4E-dependent in both sexes. We identified a robust paclitaxel-induced, eIF4E-dependent increase in spinal astrocyte immunoreactivity in males, but not females. Taken together, our data reveals that cap-dependent translation may be a key pathway that presents relevant therapeutic targets during the early phase of CIPN. By targeting the eIF4E complex, we may reduce or reverse the negative effects associated with chemotherapeutic treatments.


Subject(s)
Antineoplastic Agents, Phytogenic/toxicity , Eukaryotic Initiation Factor-4E/metabolism , Neuroimmunomodulation/drug effects , Peripheral Nervous System Diseases/chemically induced , Animals , Female , Ganglia, Spinal/drug effects , Ganglia, Spinal/metabolism , Lymphocyte Activation/drug effects , Macrophage Activation/drug effects , Male , Mice , Mice, Inbred C57BL , Nociceptors/drug effects , Nociceptors/metabolism , Paclitaxel/toxicity , Phosphorylation , Protein Biosynthesis
3.
Elife ; 72018 03 13.
Article in English | MEDLINE | ID: mdl-29533186

ABSTRACT

Recovery from serious neurological injury requires substantial rewiring of neural circuits. Precisely-timed electrical stimulation could be used to restore corrective feedback mechanisms and promote adaptive plasticity after neurological insult, such as spinal cord injury (SCI) or stroke. This study provides the first evidence that closed-loop vagus nerve stimulation (CLV) based on the synaptic eligibility trace leads to dramatic recovery from the most common forms of SCI. The addition of CLV to rehabilitation promoted substantially more recovery of forelimb function compared to rehabilitation alone following chronic unilateral or bilateral cervical SCI in a rat model. Triggering stimulation on the most successful movements is critical to maximize recovery. CLV enhances recovery by strengthening synaptic connectivity from remaining motor networks to the grasping muscles in the forelimb. The benefits of CLV persist long after the end of stimulation because connectivity in critical neural circuits has been restored.


Subject(s)
Electric Stimulation , Neurotransmitter Agents/therapeutic use , Spinal Cord Injuries/rehabilitation , Stroke Rehabilitation/methods , Animals , Female , Forelimb/physiopathology , Hand Strength/physiology , Humans , Motor Cortex/physiopathology , Neuronal Plasticity/physiology , Rats , Recovery of Function/physiology , Spinal Cord/physiopathology , Spinal Cord Injuries/physiopathology , Spinal Cord Injuries/therapy , Stroke/physiopathology , Stroke/therapy , Teach-Back Communication
4.
Proc Natl Acad Sci U S A ; 108(12): 4876-81, 2011 Mar 22.
Article in English | MEDLINE | ID: mdl-21378266

ABSTRACT

In the field of induced potency and fate reprogramming, it remains unclear what the best starting cell might be and to what extent a cell need be transported back to a more primitive state for translational purposes. Reprogramming a committed cell back to pluripotence to then instruct it toward a particular specialized cell type is demanding and may increase risks of neoplasia and undesired cell types. Precursor/progenitor cells from the organ of therapeutic concern typically lack only one critical attribute--the capacity for sustained self-renewal. We speculated that this could be induced in a regulatable manner such that cells proliferate only in vitro and differentiate in vivo without the need for promoting pluripotence or specifying lineage identity. As proof-of-concept, we generated and tested the efficiency, safety, engraftability, and therapeutic utility of "induced conditional self-renewing progenitor (ICSP) cells" derived from the human central nervous system (CNS); we conditionally induced self-renewal efficiently within neural progenitors solely by introducing v-myc tightly regulated by a tetracycline (Tet)-on gene expression system. Tet in the culture medium activated myc transcription and translation, allowing efficient expansion of homogeneous, clonal, karyotypically normal human CNS precursors ex vivo; in vivo, where Tet was absent, myc was not expressed, and self-renewal was entirely inactivated (as was tumorigenic potential). Cell proliferation ceased, and differentiation into electrophysiologically active neurons and other CNS cell types in vivo ensued upon transplantation into rats, both during development and after adult injury--with functional improvement and without neoplasia, overgrowth, deformation, emergence of non-neural cell types, phenotypic or genomic instability, or need for immunosuppression. This strategy of inducing self-renewal might be applied to progenitors from other organs and may prove to be a safe, effective, efficient, and practical method for optimizing insights gained from the ability to reprogram cells.


Subject(s)
Brain Injuries/therapy , Brain/cytology , Induced Pluripotent Stem Cells/cytology , Neural Stem Cells/cytology , Stem Cell Transplantation , Animals , Brain/metabolism , Cell Line , Cell Proliferation , Gene Expression , Humans , Induced Pluripotent Stem Cells/metabolism , Male , Neural Stem Cells/metabolism , Oncogene Protein p55(v-myc)/genetics , Oncogene Protein p55(v-myc)/metabolism , Rats , Rats, Sprague-Dawley , Transplantation, Heterologous
5.
PLoS One ; 2(12): e1272, 2007 Dec 05.
Article in English | MEDLINE | ID: mdl-18060066

ABSTRACT

Human bone marrow contains two major cell types, hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). MSCs possess self-renewal capacity and pluripotency defined by their ability to differentiate into osteoblasts, chondrocytes, adipocytes and muscle cells. MSCs are also known to differentiate into neurons and glial cells in vitro, and in vivo following transplantation into the brain of animal models of neurological disorders including ischemia and intracerebral hemorrhage (ICH) stroke. In order to obtain sufficient number and homogeneous population of human MSCs, we have clonally isolated permanent and stable human MSC lines by transfecting primary cell cultures of fetal human bone marrow MSCs with a retroviral vector encoding v-myc gene. One of the cell lines, HM3.B10 (B10), was found to differentiate into neural cell types including neural stem cells, neurons, astrocytes and oligodendrocytes in vitro as shown by expression of genetic markers for neural stem cells (nestin and Musashi1), neurons (neurofilament protein, synapsin and MAP2), astrocytes (glial fibrillary acidic protein, GFAP) and oligodendrocytes (myelin basic protein, MBP) as determined by RT-PCR assay. In addition, B10 cells were found to differentiate into neural cell types as shown by immunocytochical demonstration of nestin (for neural stem cells), neurofilament protein and beta-tubulin III (neurons) GFAP (astrocytes), and galactocerebroside (oligodendrocytes). Following brain transplantation in mouse ICH stroke model, B10 human MSCs integrate into host brain, survive, differentiate into neurons and astrocytes and induce behavioral improvement in the ICH animals. B10 human MSC cell line is not only a useful tool for the studies of organogenesis and specifically for the neurogenesis, but also provides a valuable source of cells for cell therapy studies in animal models of stroke and other neurological disorders.


Subject(s)
Bone Marrow/embryology , Mesenchymal Stem Cells/cytology , Multipotent Stem Cells/cytology , Animals , Brain/cytology , Brain/metabolism , Brain-Derived Neurotrophic Factor/metabolism , Cell Differentiation , Cell Line, Transformed , Cell Lineage , Cell Separation , Cell Transplantation , Gene Transfer Techniques , Humans , Immunohistochemistry , Male , Mice , Mice, Inbred ICR , Models, Animal , Reverse Transcriptase Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...